Abstract: 　　
　　Chimeric Antigen Receptor T-cell (CAR-T) therapy, a revolutionary technology in tumor immunotherapy, has achieved breakthroughs in the treatment of hematological malignancies. Currently, multiple CAR-T products have been approved for clinical use worldwide. However, its progress in solid tumor treatment is relatively slow, mainly due to the highly complex biological characteristics of solid tumors. In recent years, with the continuous identification of new targets in solid tumors, constant innovation of genetic engineering technologies, and increasing maturity of combination therapy strategies, the application potential of CAR-T therapy in solid tumor treatment has gradually emerged, showing broad translational prospects. This article systematically reviews the latest clinical research progress of CAR-T therapy for solid tumors, deeply analyzes the core challenges it faces and corresponding countermeasures, and provides an outlook on the future development direction of this field.
　　Chimeric Antigen Receptor T-cell (CAR-T) therapy, a revolutionary technology in tumor immunotherapy, has achieved breakthroughs in the treatment of hematological malignancies. Currently, multiple CAR-T products have been approved for clinical use worldwide. However, its progress in solid tumor treatment is relatively slow, mainly due to the highly complex biological characteristics of solid tumors. In recent years, with the continuous identification of new targets in solid tumors, constant innovation of genetic engineering technologies, and increasing maturity of combination therapy strategies, the application potential of CAR-T therapy in solid tumor treatment has gradually emerged, showing broad translational prospects. This article systematically reviews the latest clinical research progress of CAR-T therapy for solid tumors, deeply analyzes the core challenges it faces and corresponding countermeasures, and provides an outlook on the future development direction of this field.